Check out your Company Bowl for anonymous work chats.
Sartorius is part of the solution in the fight against cancer 19 million people are being diagnosed with cancer every year. To realize the great promises of biopharmaceuticals for patients worldwide, Sartorius supports its customers in simplifying their workflows - so that innovative therapies and new medications reach patients faster. Learn more about how biologics can advance the detection and treatment of cancer on the Sartorius blog: http://ow.ly/GnuS50HMHcO
Sartorius closes fiscal 2021 with 50 percent growth and a jump in profitability Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. According to preliminary figures, the company achieved significant double-digit percentage growth in order intake, sales revenue and earnings, and expects dynamic development with double-digit growth in sales revenue and sustained high profitability in the current year as well.
In 2021, on average more than 300 new colleagues went through the onboarding programs at Sartorius' sites all over the world every month. Two of them are Elly Zhang and Zhaoqing Wang, who became part of the Shanghai team in fall. Learn more about their experiences and impressions as newbies and why they decided to join the company in the first place.
Within the scope of its "Donations Instead of Gifts" initiative, Sartorius is once again supporting the medical aid organization action medeor e.V. This year’s donations are being provided to a midwifery school in Sierra Leone, a country with particularly high maternal mortality. By improving midwifery training, the project is making an important and sustainable contribution to the promotion of healthcare for mothers and their newborns. Sartorius has engaged with action medeor in a partnership for the past six years. During this time, the company has supported projects in Northern Iraq, Yemen, DR Congo and Tanzania. Learn more about this partnership.
Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH. The laboratory technology company based in Jena, Germany, develops, manufactures and markets solutions for the automated analysis, selection and isolation of cells. With these solutions, ALS enables life science customers to significantly reduce time to result and cost in cell line development and antibody discovery. Sartorius is initially purchasing 62.5 percent of the shares in ALS as of January 3, 2022. The remaining 37.5 percent will be acquired in 2026. ALS currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021.
At Sartorius IT, a team of software engineers and tech enthusiasts works together in an agile environment with a start-up culture. Together, they foster a digital customer experience: from building a digital ecosystem to the introduction of mixed reality. Learn more about how their work allows researchers to focus on achieving medical progress.
At Sartorius, Jens Heiduck and his team ensure the quality and regulatory compliance of each component that is used in Sartorius products - so that our biopharma customers can develop and produce medications reliably and safely. Find out how Jens' responsibilities and work environment have evolved over time and where the supplier quality management team is heading.
Our innovations help simplify medical progress so that better therapies will reach patients faster. What will happen to your ideas? Join our team and elevate your creativity.
Sartorius will pay a total of around 20 million euros in special bonuses to employees in appreciation of their substantial commitment and special achievements in 2021. “The second exceptional year under pandemic conditions is coming to a close. The massively increased demand for our innovative solutions that are used in the development and production of vaccines and medicines has been challenging for our employees. They have gone the extra mile, or rather many extra miles, this year to ensure that we can reliably supply our customers with much needed products, and we would like to thank them very much for their efforts. As recognition for and appreciation of their work, Sartorius will again pay a special bonus to all employees,” said Sartorius Executive Board Chairman and CEO Joachim Kreuzburg.
Sartorius officially celebrated the opening of its Cell Culture Technology Center in Ulm. The site in southern Germany features special laboratories designed to develop cell lines and optimize cell culture media. Located at Science Park III, a major hub for research and scientific discovery in close proximity to many of Germany’s top universities, the facility houses approximately 120 Sartorius employees on 65,000 square feet. Sartorius aims to expand further and is now offering a variety of positions at the site. The Mayor of Ulm, Gunter Czisch, and the President of the University of Ulm, Prof. Michael Weber, joined the opening ceremony that was held virtually due to the pandemic. Watch the guided tour of the site and meet our Ulm team.
